ProQR Therapeutics (NASDAQ:PRQR) Given Average Recommendation of “Buy” by Brokerages

ProQR Therapeutics (NASDAQ:PRQR) has been assigned a consensus recommendation of “Buy” from the six ratings firms that are presently covering the company, MarketBeat.com reports. Five equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating on the company. The average 12-month target price among analysts that have issued ratings on the stock in the last year is $8.83.

A number of equities research analysts have recently issued reports on the stock. StockNews.com downgraded shares of ProQR Therapeutics from a “hold” rating to a “sell” rating in a research note on Thursday, November 28th. HC Wainwright reissued a “buy” rating and issued a $10.00 target price on shares of ProQR Therapeutics in a research report on Thursday, December 12th. Raymond James upgraded ProQR Therapeutics from an “outperform” rating to a “strong-buy” rating and raised their price target for the stock from $6.00 to $14.00 in a research report on Tuesday, October 29th. Oppenheimer initiated coverage on ProQR Therapeutics in a report on Friday, January 10th. They issued an “outperform” rating and a $15.00 price objective on the stock. Finally, Chardan Capital reaffirmed a “buy” rating and issued a $4.00 target price on shares of ProQR Therapeutics in a research report on Thursday, December 12th.

ProQR Therapeutics Price Performance

Shares of ProQR Therapeutics stock opened at $2.40 on Friday. The firm has a market cap of $196.03 million, a PE ratio of -7.50 and a beta of 0.26. ProQR Therapeutics has a 52 week low of $1.61 and a 52 week high of $4.62. The business’s fifty day simple moving average is $2.69 and its 200-day simple moving average is $2.58.

ProQR Therapeutics (NASDAQ:PRQR) last posted its earnings results on Thursday, November 7th. The biopharmaceutical company reported ($0.11) EPS for the quarter, beating analysts’ consensus estimates of ($0.12) by $0.01. The company had revenue of $4.22 million for the quarter, compared to analysts’ expectations of $4.75 million. ProQR Therapeutics had a negative net margin of 134.31% and a negative return on equity of 71.58%. As a group, equities analysts expect that ProQR Therapeutics will post -0.31 earnings per share for the current year.

Institutional Investors Weigh In On ProQR Therapeutics

Hedge funds have recently bought and sold shares of the stock. BNP Paribas Financial Markets grew its position in shares of ProQR Therapeutics by 14.2% during the third quarter. BNP Paribas Financial Markets now owns 58,801 shares of the biopharmaceutical company’s stock worth $107,000 after buying an additional 7,300 shares in the last quarter. OneDigital Investment Advisors LLC grew its holdings in ProQR Therapeutics by 37.0% during the 3rd quarter. OneDigital Investment Advisors LLC now owns 57,550 shares of the biopharmaceutical company’s stock worth $105,000 after acquiring an additional 15,550 shares in the last quarter. Ballentine Partners LLC purchased a new stake in shares of ProQR Therapeutics in the 4th quarter valued at approximately $61,000. Privium Fund Management B.V. increased its position in shares of ProQR Therapeutics by 0.9% in the 3rd quarter. Privium Fund Management B.V. now owns 5,632,388 shares of the biopharmaceutical company’s stock valued at $10,251,000 after purchasing an additional 51,663 shares during the last quarter. Finally, Raymond James Financial Inc. acquired a new stake in shares of ProQR Therapeutics in the 4th quarter valued at $260,000. Institutional investors and hedge funds own 32.65% of the company’s stock.

ProQR Therapeutics Company Profile

ProQR Therapeutics N.V., a biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company's products pipeline includes AX-0810 for cholestatic diseases targeting Na-taurocholate cotransporting polypeptide (NTCP); and AX-1412 for cardiovascular diseases (CVDs) targeting Beta-1,4-galactosyltransferase 1 (B4GALT1).